The annual meeting of the American Society for Radiation Oncology was held from Sept. 26 to 30 in Boston, and gathered physicians, oncology nurses, radiation therapists, biologists, physicists, and other cancer researchers. The conference featured educational courses focusing on radiation, surgical, and medical oncology.
ASTRO: Low-Dose Radiotherapy Shows Potential in Early Knee Osteoarthritis
THURSDAY, Oct. 8, 2026 (HealthDay News) -- Low-dose radiotherapy offers multiple benefits in early knee osteoarthritis, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 26 to 30 in Boston.
ASTRO: Stereotactic Radiosurgical Capsulotomy Promising in Treatment-Resistant Depression
WEDNESDAY, Oct. 7, 2026 (HealthDay News) -- For patients with treatment-resistant major depressive disorder, stereotactic radiosurgical capsulotomy shows promise, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 26 to 30 in Boston.
ASTRO: Fractionated Radiosurgery Boosts Survival With Brain Metastases
TUESDAY, Oct. 6, 2026 (HealthDay News) -- After resection of larger brain metastases, fractionated stereotactic radiosurgery offers superior surgical bed control than single-fraction stereotactic radiosurgery, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 26 to 30 in Boston.
ASTRO: Cancer-Specific Mortality Elevated for Patients With Cancer and Depression
MONDAY, Oct. 5, 2026 (HealthDay News) -- The risk for cancer-specific mortality is significantly higher for patients with cancer and preexisting depression, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 26 to 30 in Boston.
ASTRO: <30 Percent With ER+ Early-Stage Breast Cancer Remain on Endocrine Therapy at Five Years
MONDAY, Oct. 5, 2026 (HealthDay News) -- Less than 30 percent of women with estrogen receptor-positive early-stage breast cancer treated with lumpectomy remain adherent to endocrine therapy at five years, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 26 to 30 in Boston.
